Business Context and Reporting Period
Outlook Therapeutics, Inc. (OTLK) filed a Form 8-K on March 10, 2026, reporting the results of its Annual Meeting of Stockholders held on the same date. The company is incorporated in Delaware and trades on The Nasdaq Stock Market LLC.
Key Financial Metrics
This filing is a Current Report regarding corporate governance matters and does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for any financial metric.
Material Changes and Voting Results
Of the 73,509,455 shares outstanding, 37,271,431 shares (approximately 50.70%) were present or represented by proxy. Stockholders voted on three proposals:
- Proposal 1 (Election of Directors): Three Class I directors were elected to serve until the 2029 Annual Meeting.
- Yezan Haddadin: 14,266,442 votes for; 1,349,917 against; 142,673 withheld; 21,512,399 broker non-votes.
- Faisal G. Sukhtian: 14,192,499 votes for; 1,161,669 against; 404,864 withheld; 21,512,399 broker non-votes.
- Kurt J. Hilzinger: 14,556,823 votes for; 972,667 against; 229,542 withheld; 21,512,399 broker non-votes.
- Proposal 2 (Ratification of Auditors): Stockholders ratified the selection of KPMG LLP as the independent registered public accounting firm for the fiscal year ending September 30, 2026.
- Results: 35,628,284 votes for; 751,849 against; 891,298 abstentions; 0 broker non-votes.
- Proposal 3 (Executive Compensation): Stockholders approved a non-binding advisory vote on the compensation of named executive officers.
- Results: 13,873,653 votes for; 1,501,567 against; 383,812 abstentions; 21,512,399 broker non-votes.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, risk factors, or contingencies. It strictly reports the certified results of the shareholder vote.
Key Facts for Investor Verification
- Verify the full text of the Proxy Statement filed on January 26, 2026, for detailed background on the director nominees and executive compensation.
- Note the significant number of broker non-votes (21,512,399) on Proposals 1 and 3, indicating shares held by brokers that were not voted due to lack of instructions.
- Confirm the re-election of the Class I directors and the ratification of KPMG LLP for the fiscal year ending September 30, 2026.
- Review subsequent filings (e.g., 10-K or 10-Q) for financial performance data, as this 8-K does not include financial metrics.